Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Summary. Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...

Blueprint Medicines' stock was stagnant in 2024 and is up just 2% since my rating upgrade to "strong buy" in February.Back then, my focus was on the company's lead drug, Ayvakit, to treat advanced ...

Blueprint Medicines (NASDAQ:BPMC) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

After reporting second-quarter financial results and updating investors on the progress it's making in developing cancer therapies targeting specific genetic mutations, Blueprint Medicines (NASDAQ ...